<DOC>
	<DOCNO>NCT01408563</DOCNO>
	<brief_summary>This trial use two cord blood unit transplantation use reduce intensity regimen rather use intense dos chemotherapy radiation therapy . Two cord blood unit ( double cord blood ) use , number blood cell one unit allow successful growth cell . Because risk infection , particularly virus infection , high double cord blood transplant , study seek reduce rise virus infection use reduce intensity regimen without medicine call antithymocyte globulin ( ATG ) , use prior cord blood transplant . Subjects receive two chemotherapy drug , melphalan fludarabine , low dose total body radiation ( one treatment ) instead ATG . The number patient virus infection study compare prior experience use ATG .</brief_summary>
	<brief_title>Reduced Intensity Double Umbilical Cord Blood Transplantation</brief_title>
	<detailed_description>Subjects receive transplant in-patients . - IV-Catheter - one two IV catheter place day hospital admission - Conditioning - Fludarabine IV six day transplant ( day -7 , -6 , -5 . -4 , -3 , -2 ) - Melphalan IV ( day -1 ) - Total body radiation day 0 ( day transplant ) - Immunosuppressive Therapy - Tacrolimus sirolimus begin day -3 , daily 6-9 month post-transplant . Given IV in-patient , orally out-patient - Infusion Cord Blood unit - 2 cord blood unit IV Day 0 Routine post-transplant supportive care provide</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Hematologic malignancy allogeneic stem cell transplantation deem clinically appropriate Appropriate candidate reduce intensity regimen , accord treat physician Lack 6/6/ 5/6 HLAmatched relate , 8/8/ HLAmatched unrelated donor , unrelated donor available time frame necessary perform potentially curative stem cell transplant Able comply requirement care allogeneic stem cell transplantation Cardiac disease : symptomatic congestive heart failure evidence leave ventricular dysfunction Pulmonary disease : symptomatic chronic obstructive lung disease , symptomatic restrictive lung disease Renal disease Hepatic disease Neurologic disease : symptomatic leukoencephalopathy , active CNS malignancy neuropsychiatric abnormality believe preclude transplantation HIVpositive Uncontrolled infection Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>NHL</keyword>
	<keyword>lymphoma</keyword>
	<keyword>leukemia</keyword>
	<keyword>myelodysplastic disorder</keyword>
	<keyword>aplastic anemia</keyword>
</DOC>